Douglas S. Ingram

Douglas S. Ingram (chief executive) discloses dealings in 4 companies, chiefly Sarepta Therapeutics, Inc., Endo International plc and Arrowhead Pharmaceuticals, Inc. Over a trading history stretching from 5 May 2016 to 16 December 2025, the count stands at 30 filings.

Both buying and selling appear: 13 purchases worth €12.8M, against 1 sale worth €105k. The net balance comes to €12.7M on the buying side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 16 share grants.

A typical purchase (the median) is worth €857k. Clusters matter here: 5 out of 13 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.

Most recently, on 18 December 2025, the filings show a share grant in Arrowhead Pharmaceuticals, Inc. The most recent open-market purchase was published on 6 November 2023, 1,082 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.